Receipt of Partial Withdrawal of Shareholder Proposal and Agenda Items for the 108th Annual General Meeting of Shareholders
At the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, the shareholder proposal to elect one auditor was withdrawn, and the Company’s Board of Directors consented to this withdrawal.
Notice Regarding Partial Amendment of Articles of Incorporation Due to Transition to a Company with an Audit and Supervisory Committee
Kobayashi Pharmaceutical Co., Ltd. plans to propose amendments to its articles of incorporation at the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, to transition to a company with an audit and supervisory committee, aiming to strengthen the board of directors' supervisory functions and improve management agility.
Notice Concerning Dividend of Surplus and Withdrawal of Special Reserves
The year-end dividend for the fiscal year ending December 2025 is 60 yen per share, with a total dividend amount of 4,460 million yen. A transfer of 8,300 million yen from special reserves to retained earnings will be made, effective March 9, 2026.
Financial Summary for the Fiscal Year Ending December 2025 [Japanese GAAP] (Consolidated)
For the fiscal year ending December 2025, consolidated net sales were JPY 165,742 million (up 0.1% YoY), operating income was JPY 14,923 million (down 40.0% YoY), and net income attributable to owners of the parent was JPY 3,656 million (down 63.7% YoY).
Notice Regarding the Formulation of Medium-Term Management Plan (2026-2028)
The sales target for the fiscal year ending December 2028 is 188 billion yen (CAGR +4.3%), operating income 22 billion yen (CAGR +13.8%), and ROE 10%, aiming for 30 consecutive years of dividend increases.
Notice on Progress of Recurrence Prevention Measures
Kobayashi Pharmaceutical provides a detailed report on the progress of recurrence prevention measures for quality issues related to red yeast rice products, promoting strengthening of a quality and safety-first system and organizational culture reform.
Notice Regarding Transition to a Company with an Audit and Supervisory Committee
Kobayashi Pharmaceutical Co., Ltd. will transition from a company with a board of auditors to a company with an audit and supervisory committee, subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, to strengthen its corporate governance framework.
Notice Regarding Executive Personnel Changes Following Transition to a Company with an Audit and Supervisory Committee
Subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, the company will transition from a company with a board of auditors to a company with an Audit and Supervisory Committee and has decided on new executive candidates.
Notice Regarding the Board of Directors’ Opinion on Shareholder Proposals
Regarding the four shareholder proposals at the 108th Annual General Meeting of Shareholders to be held on March 27, 2026, the Company's Board of Directors opposes all proposals and recommends shareholders to vote against them.
Notice Regarding Recording of Extraordinary Loss (Impairment Loss), Revision of Full-Year Earnings Guidance, and Differences Between Individual Earnings Forecast and Previous Fiscal Year Results
Recorded an impairment loss of 14,645 million yen on fixed assets in the fiscal year ending December 2025, revising the full-year consolidated net income forecast downward by 65.7% to 3,600 million yen.
Notice Regarding Change of Largest Major Shareholder
As of December 22, 2025, the largest major shareholder has changed to Oasis Management Company Limited.
